Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables



      The aim of this study was to compare effects of the transdermal contraceptive patch, a desogestrel/ethinyl estradiol (EE)-containing, monophasic combination oral contraceptive (COC) and a levonorgestrel/EE-containing, triphasic COC on hemostasis variables.

      Study Design

      This was a randomized, open-label study of 104 young women who received six cycles of treatment. Blood was collected at baseline and on treatment; changes by Day 20/Cycle 6 in baseline hemostasis markers [prothrombin fragment 1+2 (F 1+2), plasmin���plasmin inhibitor complex (PAP) and fibrin degradation products (d-dimer)] were assessed.


      All contraceptives induced similar increases in F 1+2 and d-dimer. Patch-induced PAP increases were less than with the monophasic and similar to the triphasic COC. Decreases in protein S and increases in sex hormone-binding globulin were greater with the patch than with either COC. Patch-induced increases in activated protein C resistance were greater than with the triphasic and similar to the monophasic COC.


      These contraceptives appeared to accelerate baseline procoagulation processes to a similar extent and to change coagulation potency variables differently.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kluft C.
        • Lansink M.
        Effect of oral contraceptives on hemostasis variables.
        Thromb Haemost. 1997; 78: 315-326
        • Vandenbroucke J.P.
        • Rosing J.
        • Blomenkamp K.W.
        • et al.
        Oral contraceptives and the risk of venous thrombosis.
        N Engl J Med. 2001; 344: 1527-1535
        • Phillips A.
        • Demarest K.
        • Hahn D.W.
        • Wong F.
        • McGuire J.L.
        Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
        Contraception. 1990; 41: 399-410
        • Kluft C.
        • Meijer P.
        • Helmerhorst F.M.
        • Hall H.
        • Creasy G.
        Comparison of the effects of a contraceptive patch and oral contraceptives on coagulation parameters.
        in: Presented at the International Federation of Gynecology and Obstetrics (FIGO)2000 (Abstract FC2.30.4)
        • Rosing J.
        • Tans G.
        • Nicolaes G.A.F.
        • et al.
        Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
        Br J Haematol. 1997; 97: 233-238
        • Heinemann L.A.J.
        • Kluft C.
        • Spannagl M.
        • deMaat M.P.
        The association between extrinsic activated protein C resistance and venous thromboembolism in women.
        Contraception. 2002; 66: 297-304
        • De Maat M.M.
        • de Bart A.W.
        • Hennis B.C.
        • et al.
        Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris.
        Arterioscler Thromb Vasc Biol. 1996; 16: 1156-1162
      1. European Medicines' Evaluation Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP).
        Guideline on clinical investigation of steroid contraceptives in women. EMEA, London, UK2006
        • Miller G.J.
        • Bauer K.A.
        • Barzegar S.
        • et al.
        The effect of quality and timing of venipuncture on markers of blood coagulation in healthy middle-aged men.
        Thromb Haemost. 1995; : 7382-7386
        • Kyrle P.A.
        • Eichinger S.
        • Pabinger I.
        • et al.
        Prothrombin fragment F 1+2 is not predictive for recurrent venous thromboembolism.
        Thromb Haemost. 1997; 77: 829-833
        • The Oral Contraceptive and Hemostasis Study Group
        The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.
        Contraception. 2003; 67: 173-185
        • Kemmeren J.M.
        • Algra A.
        • Meijers J.C.
        • Bouma B.N.
        • Grobbee D.E.
        Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation.
        Blood Coagul Fibrinolysis. 2002; 13: 373-381
        • Oelkers W.K.
        Effects of estrogens and progestogens on the renin���aldosterone system and blood pressure.
        Steroids. 1996; 61: 166-171
        • Van der Vange N.
        • Blankenstein M.A.
        • Kloosterboer H.J.
        • Haspels A.A.
        • Thijssen J.H.
        Effects of seven low-dose combined oral contraceptives on sex hormone-binding globulin, corticosteroid binding globulin, total and free testosterone.
        Contraception. 1990; 41: 345-352